(Q37842120)

24 August 2017

1 reference

title

Pharmacological strategies for lowering LDL cholesterol: statins and beyond (English)

1 reference

24 August 2017

1 reference

Ariel Brautbar

1

1 reference

PubMed ID

21321561

24 August 2017

Christie M Ballantyne

series ordinal

2

1 reference

PubMed ID

21321561

24 August 2017

language of work or name

English

0 references

publication date

15 February 2011

1 reference

Nature Reviews Cardiology

24 August 2017

1 reference

24 August 2017

8

1 reference

24 August 2017

5

1 reference

24 August 2017

253-265

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

24 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by rep

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Do structural differences in statins correlate with clinical efficacy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Rosuvastatin in older patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Molecular diagnosis of hypobetalipoproteinemia: an ENID review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Progress in antisense technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Antisense technologies. Improvement through novel chemical modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Monogenic hypercholesterolemia: new insights in pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

A new method for measurement of total plasma PCSK9: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Lipid lowering with thyroid hormone and thyromimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

A receptor-mediated pathway for cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Reply to Chesson et al.: Carbon stable isotopes in beef differ distinctly between corporations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Abetalipoproteinemia. New insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.2

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

31 March 2020

1 reference

12 December 2020

Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review.

1 reference

12 December 2020

Clofibrate and niacin in coronary heart disease

1 reference

12 December 2020

Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.

1 reference

12 December 2020

Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRCARDIO.2011.2

1 reference

24 August 2017

1 reference

PubMed ID

21321561